NCT01554241

Brief Summary

Vitamin D deficiency is highly prevalent in older people in the absence of vitamin D supplementation. The limited data available show marked inter-individual variability in response to vitamin D supplementation in very old, frail elderly with almost 25% remaining vitamin D deficient (25-OH D \< 20 ng/mL) when receiving the currently recommended 800 IU/day vitamin D. This proposal is for exploratory research on the use of a wide range of oral vitamin D3 doses in frail elderly living in controlled living environments.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
86

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Sep 2012

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 12, 2012

Completed
2 days until next milestone

First Posted

Study publicly available on registry

March 14, 2012

Completed
6 months until next milestone

Study Start

First participant enrolled

September 1, 2012

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2014

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2014

Completed
6 months until next milestone

Results Posted

Study results publicly available

February 18, 2015

Completed
Last Updated

February 18, 2015

Status Verified

February 1, 2015

Enrollment Period

2 years

First QC Date

March 12, 2012

Results QC Date

January 23, 2015

Last Update Submit

February 13, 2015

Conditions

Keywords

vitamin D3D3cholecalciferol25-OH vitamin Delderlynursing home resident

Outcome Measures

Primary Outcomes (1)

  • Total 25-OH Vitamin D3 Level

    circulating total 25-OH vitamin D concentration

    16 weeks

Secondary Outcomes (1)

  • Free 25-OH Vitamin D3

    16 weeks

Study Arms (4)

vitamin D3 800 IU/day

EXPERIMENTAL

recommended daily dosage of 800 IU/day D3

Dietary Supplement: vitamin D3 800 IU/day

2000 IU/day D3

EXPERIMENTAL

D3 2000 IU/day

Dietary Supplement: D3 2000 IU/day

vitamin D3 4000 IU/day

EXPERIMENTAL

D3 4000 IU/day

Dietary Supplement: D3 4000 IU/day

50,000 IU/week D3

EXPERIMENTAL

D3 50,000 IU weekly

Dietary Supplement: D3 50,000 IU weekly

Interventions

D3 2000 IU/dayDIETARY_SUPPLEMENT

2000 IU/day D3

Also known as: cholecalciferol
2000 IU/day D3
D3 4000 IU/dayDIETARY_SUPPLEMENT

vitamin D3 4000 IU/day

Also known as: cholecalciferol
vitamin D3 4000 IU/day
D3 50,000 IU weeklyDIETARY_SUPPLEMENT

vitamin D3 50,000 IU/week

Also known as: cholecalciferol
50,000 IU/week D3
vitamin D3 800 IU/dayDIETARY_SUPPLEMENT

vitamin D3 800 IU/day

Also known as: cholecalciferol
vitamin D3 800 IU/day

Eligibility Criteria

Age65 Years+
Sexall
Healthy VolunteersNo
Age GroupsOlder Adult (65+)

You may qualify if:

  • age over 65
  • medically stable
  • residing in long-term care or assisted living

You may not qualify if:

  • hypercalcemia or high risk for hypercalcemia
  • active cancer or malignancy other than non-melanoma skin cancer
  • severe renal disease (eGFR \<30 ml/mkin/M2)
  • small bowel resection or intestinal bypass surgery
  • hyperparathyroidism
  • granulomatous disease
  • clinically unstable (changes in medications or diagnoses within a month, hospitalizations, within 6 months)
  • allergy to vitamin D

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of California

San Francisco, California, 94143, United States

Location

MeSH Terms

Interventions

Cholecalciferol

Intervention Hierarchy (Ancestors)

CholestenesCholestanesSteroidsFused-Ring CompoundsPolycyclic CompoundsSterolsVitamin DSecosteroidsMembrane LipidsLipids

Results Point of Contact

Title
Janice B.Schwartz, M.D., Professor of Medicine
Organization
University of California, San Francisco

Study Officials

  • Janice B Schwartz, MD

    University of California, San Francisco

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 12, 2012

First Posted

March 14, 2012

Study Start

September 1, 2012

Primary Completion

September 1, 2014

Study Completion

September 1, 2014

Last Updated

February 18, 2015

Results First Posted

February 18, 2015

Record last verified: 2015-02

Locations